Skip to Main Content
Beta test
our new site.
(
NLM Technical Bulletin
)
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Topical Rapamycin Therapy to Alleviate Cutaneous Manifestations of Tuberous Sclerosis Complex (TSC) and Neurofibromatosis I (NF1)
This study has been completed.
Study NCT01031901 Information provided by The University of Texas Health Science Center, Houston
First Received on December 10, 2009. Last Updated on February 24, 2012
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Tuberous Sclerosis
Neurofibromatoses
Angiofibroma
Neurofibroma
Additional conditions recognized in this trial
Neurofibromatosis 1
Sclerosis
More general conditions related to this trial
Congenital Abnormalities
Genetic Diseases, Inborn
Hamartoma
Heredodegenerative Disorders, Nervous System
Malformations of Cortical Development
Neoplasms
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Neoplasms, Vascular Tissue
Neoplastic Syndromes, Hereditary
Nerve Sheath Neoplasms
Nervous System Diseases
Nervous System Malformations
Nervous System Neoplasms
Neurocutaneous Syndromes
Neurodegenerative Diseases
Neuromuscular Diseases
Pathologic Processes
Peripheral Nervous System Diseases
Peripheral Nervous System Neoplasms
Interventions listed in this trial
Skincerity
Skincerity plus sirolimus/rapamycin
Skinercity plus sirolimus/rapamycin
Additional drug interventions recognized in this trial
Everolimus
Sirolimus
More general drug interventions related to this trial
Anti-Bacterial Agents
Anti-Infective Agents
Antibiotics, Antineoplastic
Antifungal Agents
Antineoplastic Agents
Immunologic Factors
Immunosuppressive Agents
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
The University of Texas Health Science Center, Houston
Society for Pediatric Dermatology
Back to top of Main Content
